Display options
Cite
Frohlich ED, Aristizabal D, Soria F, et al. Investigative Concerns in Demonstrating Reduced Risk From Reversing Left Ventricular Hypertrophy. J Cardiovasc Pharmacol Ther. 1996;1(1):17-22doi: 10.1177/107424849600100104.
Frohlich, E. D., Aristizabal, D., Soria, F., & Messerli, F. H. (1996). Investigative Concerns in Demonstrating Reduced Risk From Reversing Left Ventricular Hypertrophy. Journal of cardiovascular pharmacology and therapeutics, 1(1), 17-22. https://doi.org/10.1177/107424849600100104
Frohlich, et al. "Investigative Concerns in Demonstrating Reduced Risk From Reversing Left Ventricular Hypertrophy." Journal of cardiovascular pharmacology and therapeutics vol. 1,1 (1996): 17-22. doi: https://doi.org/10.1177/107424849600100104
Frohlich ED, Aristizabal D, Soria F, Messerli FH. Investigative Concerns in Demonstrating Reduced Risk From Reversing Left Ventricular Hypertrophy. J Cardiovasc Pharmacol Ther. 1996 Jan;1(1):17-22. doi: 10.1177/107424849600100104. PMID: 10684395.
Copy Download .nbib Format: NLM
Share it on

J Cardiovasc Pharmacol Ther. 1996 Jan;1(1):17-22. doi: 10.1177/107424849600100104.

Investigative Concerns in Demonstrating Reduced Risk From Reversing Left Ventricular Hypertrophy.

Journal of cardiovascular pharmacology and therapeutics

Frohlich, Aristizabal, Soria, Messerli

Affiliations

  1. Alton Ochsner Medical Foundation, New Orleans, Louisiana, USA

PMID: 10684395 DOI: 10.1177/107424849600100104

Abstract

BACKGROUND: To demonstrate reduced risk from reversing left ventricular hypertrophy (LVH) in hypertension, one must show that it is independent of blood pressure reduction. METHODS AND RESULTS: A feasibility study was conducted with 15 patients. The study employed 48-hour Holter recording, exercise treadmill (for ST-segment changes) and, as necessary, thallium scintigraphy and coronary angiography. All patients were treated for 3 months with quinapril (10 mg) and demonstrated decreased mean arterial pressure (125 +/- 3.1 vs 103 +/- 1.9 mmHg; P <.01) and left ventricular mass index (125 +/- 6.4 vs 104 +/- 4.9; P <.02) with preserved left ventricular function. There were no significant changes in these patients with moderate LVH in the incidence of arrhythmias; however, 4 of the 15 patients developed ST-segment changes prior to LVH reversal, and these changes did not recur in 3 patients following reversal of LVH or when pressure was allowed to rise. CONCLUSIONS: Ischemic changes, rather than development of arrhythmias, may be of greater value in demonstrating risk reduction with LVH reversal. Moreover, these preliminary data suggest pitfalls in demonstrating risk reduction after LVH reversal, indicating that more sensitive and adequate techniques are necessary to show risk reduction from LVH.

Publication Types